Background: llmofosine is an ether lipid with antineoplastic activity in experimental systems. Since there is no established systemic treatment for metastatic renal cell cancer, a trial with this new agent seemed to be warranted. Patients and Methods: Patients with measurable metastatic renal cell cancer without prior systemic treatment received llmofosine between 150 and 300 mg per day orally until disease progression. Results: There have been no objective responses among the 19 evaluable patients. Dose-limiting toxicity was gastrointestinal intolerance. Conclusions: Oral llmofosine is ineffective in metastatic renal cell cancer.

Keywords:
Llmofosine, Renal cell cancer, Phase II study, Gastrointestinal toxicity
This content is only available via PDF.
© 1994 S. Karger AG, Basel
1994
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.